Silke Gillessen gives a summary of the 2024 Advanced Prostate Cancer Consensus Conference, covering key aspects of the meeting including surgery versus RT, genetic and somatic testing, PSMA imaging, and first-line triplet therapy. Professor Gillessen serves as the Genitourinary Cancer Systemic Therapy Research Chair at the University of Manchester, and is Head of the Department of Medical Oncology, at the Università della Svizzera Italiana in Lugano, and Director of the Oncology Institute of Southern Switzerland in Bellinzona, Switzerland. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
Chris Sweeney is joined by fellow experts to discuss mHSPC side effects such as bone weakness, hot flashes, and gynecomastia.
Professor Thomas Suter and Dr. Chuck Ryan discuss cardiovascular risks associated with hormone therapy in prostate cancer.
Drs. Thomas Zilli and Pierre Blanchard debate the use of radiation therapy in prostate cancer and oligometastatic disease.
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou on the data for and against radiation therapy in prostate cancer.
Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC.
Daniel Goldstein returns to the podcast to discuss dosing changes in drugs such as nivolumab and pembrolizumab.
Advertisement
The Uromigos: Live & Unplugged 2023
Dr. Powles chaired a livestreamed RCC session that included lively discussion from Drs. Atkins, McDermott, and Rini.
The panel highlights a serious of relevant studies in renal cell carcinoma, including CONTACT-03 and TiNivo-2.
The panel discusses data related to RLTs in prostate cancer, including a recap of the VISION trial and the PSMAfore trial.
The panel breaks down the details of the PROpel, TALAPRO-2, and MAGNITUDE trials along with relevant rPFS and HR data.
Kidney Cancer Discussions
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
